ImaRx Therapeutics, Inc.
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Published in Medical Letter on the CDC and FDA, February 10th, 2008
ImaRx Therapeutics, Inc. (NASDAQ:IMRX) announced that the Food and Drug Administration (FDA) has approved the company's most current lot release request for urokinase drug product. This is the first lot to be released with extended expiration dating. Urokinase, ImaRx's first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.
"The FDA approval of urokinase lot release brings several advantages to ImaRx," said Bradford A. Zakes, President and CEO of ImaRx. "The extended expiration dating allows us to unlock the value from our unlabeled urokinase inventory. We will also...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Depression
Selective reporting of antidepressant trials exaggerates drug effectiveness - Pediatrics
National study will look at German-made heart pump for children needing heart transplants - Atrial Fibrillation
Independent Clinical Trial Finds HIFU Surgical Ablation Effective in Treating Atrial Fibrillation - Clinical Research
Scientists at Amgen, Inc. discuss research in clinical research - Diabetes
Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells - Regulatory Actions
Stryker Issues Statement Regarding FDA Warning Letter - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
